Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats

Sorafenib (SOR), an inhibitor of multiple kinases, is a classic targeted drug for advanced hepatocellular carcinoma (HCC) which often coexists with type 2 diabetes mellitus (T2DM). Dapagliflozin (DAPA), a sodium–glucose cotransporter-2 inhibitor (SGLT2i), is widely used in patients with T2DM. Notabl...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Xueru He, Ying Li, Yinling Ma, Yuhao Fu, Xuejiao Xun, Yanjun Cui, Zhanjun Dong
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-09-01
Edice:	Molecules
Témata:	UPLC-MS/MS sorafenib dapagliflozin pharmacokinetics drug–drug interactions
On-line přístup:	https://www.mdpi.com/1420-3049/27/19/6190
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!